APA (7th ed.) Citation

Cooper, D. A., Cordery, D. V., Zajdenverg, R., Ruxrungtham, K., Arastéh, K., Bergmann, F., . . . team, s. (2016). Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Cooper, David A., et al. Tipranavir/Ritonavir (500/200 Mg and 500/100 Mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 Mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. Public Library of Science (PLoS), 2016.

MLA (9th ed.) Citation

Cooper, David A., et al. Tipranavir/Ritonavir (500/200 Mg and 500/100 Mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 Mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial. Public Library of Science (PLoS), 2016.